Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1102 in relapsing-remitting multiple sclerosis
ACTRN12608000226303Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Feb 2005
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of avicursen in multiple sclerosis (MS), sponsored by Percheron Therapeutics Ltd. Primary endpoint: Cumulative number of new active lesions on MRI, corrected for baseline enhancing lesions. Started Feb 2005; status: completed.
02
Drugs
avicursen
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12608000226303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000226303.